RAD51C种系突变携带者的乳腺癌和卵巢癌的病理特征。 - Suppr

Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers.

作者信息

Gevensleben Heidrun, Bossung Verena, Meindl Alfons, Wappenschmidt Barbara, de Gregorio Nikolaus, Osorio Ana, Romero Atocha, Buettner Reinhard, Markiefka Birgid, Schmutzler Rita Katharina

机构信息

Institute of Pathology, University Hospital Bonn, Sigmund-Freud-Strasse 25, 53127, Bonn, Germany,

出版信息

Virchows Arch. 2014 Sep;465(3):365-9. doi: 10.1007/s00428-014-1619-1. Epub 2014 Jul 4.

DOI:10.1007/s00428-014-1619-1

PMID:24993905

Abstract

摘要

相似文献

Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers.

Virchows Arch. 2014 Sep;465(3):365-9. doi: 10.1007/s00428-014-1619-1. Epub 2014 Jul 4.

Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.

J Natl Cancer Inst. 2017 Aug 1;109(8). doi: 10.1093/jnci/djw329.

High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.

Gynecol Oncol. 2008 Feb;108(2):433-7. doi: 10.1016/j.ygyno.2007.09.035. Epub 2007 Nov 7.

Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.

Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. doi: 10.1006/gyno.2000.5861.

RAD51C germline mutations found in Spanish site-specific breast cancer and breast-ovarian cancer families.

Breast Cancer Res Treat. 2014 Aug;147(1):133-43. doi: 10.1007/s10549-014-3078-4. Epub 2014 Aug 3.

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.

Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.

Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations.

J Med Genet. 2005 Mar;42(3):e20. doi: 10.1136/jmg.2004.027243.

A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?

Crit Rev Oncol Hematol. 2018 Jul;127:29-41. doi: 10.1016/j.critrevonc.2018.05.008. Epub 2018 May 14.

Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.

J Natl Cancer Inst. 2009 Jan 21;101(2):80-7. doi: 10.1093/jnci/djn442. Epub 2009 Jan 13.

A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques.

Fam Cancer. 2005;4(2):89-96. doi: 10.1007/s10689-004-5812-2.

引用本文的文献

Expression of RAD51 and Its Clinical Impact in Oral Squamous Cell Carcinoma.

Anal Cell Pathol (Amst). 2020 Mar 3;2020:1827676. doi: 10.1155/2020/1827676. eCollection 2020.

A dominant RAD51C pathogenic splicing variant predisposes to breast and ovarian cancer in the Newfoundland population due to founder effect.

Mol Genet Genomic Med. 2020 Feb;8(2):e1070. doi: 10.1002/mgg3.1070. Epub 2019 Nov 28.

Contribution of germline deleterious variants in the RAD51 paralogs to breast and ovarian cancers.

Eur J Hum Genet. 2017 Dec;25(12):1345-1353. doi: 10.1038/s41431-017-0021-2. Epub 2017 Nov 8.

Estrogen induces RAD51C expression and localization to sites of DNA damage.

Cell Cycle. 2016 Dec;15(23):3230-3239. doi: 10.1080/15384101.2016.1241927. Epub 2016 Oct 18.

Rad51c- and Trp53-double-mutant mouse model reveals common features of homologous recombination-deficient breast cancers.

Oncogene. 2016 Sep 1;35(35):4601-10. doi: 10.1038/onc.2015.528. Epub 2016 Jan 25.

Genotype/Phenotype correlations in patients with hereditary breast cancer.

Breast Care (Basel). 2015 Feb;10(1):22-6. doi: 10.1159/000380900.

本文引用的文献

Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status.

Sci Rep. 2014 Feb 7;4:4026. doi: 10.1038/srep04026.

RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families.

Breast Cancer Res. 2013 Dec 20;15(6):R120. doi: 10.1186/bcr3589.

High nuclear poly(adenosine diphosphate-ribose) polymerase expression is predictive for BRCA1- and BRCA2-deficient breast cancer.

J Clin Oncol. 2011 Dec 1;29(34):4586-8; author reply 4588. doi: 10.1200/JCO.2011.38.1988. Epub 2011 Oct 24.

RAD51C is a susceptibility gene for ovarian cancer.

Hum Mol Genet. 2011 Aug 15;20(16):3278-88. doi: 10.1093/hmg/ddr229. Epub 2011 May 25.

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.

Nat Genet. 2010 May;42(5):410-4. doi: 10.1038/ng.569. Epub 2010 Apr 18.

Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3606-14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Pathological features of breast and ovarian cancers in RAD51C germline mutation carriers.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献